Download PDF

1. Company Snapshot

1.a. Company Description

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers.The company operates in two segments, CooperVision and CooperSurgical.The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific.


The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide.It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing.The Cooper Companies, Inc.


was founded in 1958 and is headquartered in San Ramon, California.

Show Full description

1.b. Last Insights on COO

The Cooper Companies' recent performance was driven by strong Q4 earnings, beating estimates with $1.15 per share, and upbeat financial guidance. A strategic review was initiated to enhance shareholder value, fueling optimism. The company's premium lens strategy, led by MiSight myopia leadership, and fertility portfolio are growth drivers. A $1 billion share repurchase program expansion also bolstered investor sentiment. MyDAY momentum offset softness in Clariti and APAC, driving revenue and earnings growth. International revenue reliance and key metrics versus estimates also garnered attention.

1.c. Company Highlights

2. Cooper Companies' Q1 2026 Earnings: A Strong Start to the Fiscal Year

The Cooper Companies reported a robust first quarter with consolidated revenues reaching $1.024 billion, up 6.2% or 2.9% organically. CooperVision revenue was $695 million, up 7.6% or 3.3% organically, driven by the global rollout of the premium MyDay daily silicone hydrogel portfolio. Non-GAAP earnings grew 20% to $1.10, beating analyst estimates of $1.03. The company's strong profitability was accompanied by robust cash flow, with free cash flow reaching $159 million.

Publication Date: Mar -07

📋 Highlights
  • Revenue Growth:: Consolidated revenues reached $1.024 billion, up 6.2% (2.9% organically), driven by CooperVision's $695 million (up 7.6%) and CooperSurgical's $329 million (up 3.3%).
  • Non-GAAP Earnings & Cash Flow:: Non-GAAP earnings rose 20% to $1.10, while free cash flow hit $159 million, with $92 million in stock repurchases and $2.4 billion net debt reduction.
  • Guidance Raises:: Revenue guidance increased to $4.3–4.35 billion, with earnings guidance of $4.58–4.66, reflecting stronger performance and disciplined capital allocation.
  • Product Launch Impact:: MyDay silicone hydrogel and MiSight (myopia control) drove growth, with MiSight expected to grow 20–25% in 2026 and MyDay MiSight launching in multiple regions.
  • Regional Performance:: Americas and EMEA showed momentum, while Asia Pac faced Japan hydrogel challenges; full-year free cash flow remains above $2.2 billion, with $1 billion in buyback authorization.

Segment Performance

CooperVision drove growth with its premium MyDay daily silicone hydrogel portfolio, while CooperSurgical delivered revenue of $329 million, up 3.3% or 2.2% organically, with growth in fertility and office and surgical sales. The company's product launches, including MiSight in Japan and MyDay MiSight in Europe and Asia, are expected to drive growth over the next year or two.

Guidance and Outlook

The company raised guidance for both earnings and free cash flow, with revenue expectations of $4.3 billion to $4.35 billion, and earnings guidance of $4.58 to $4.66. The company expects to generate more than $2.2 billion of free cash flow from 2026 through 2028, driven by stronger operating performance, better working capital management, and lower CapEx.

Valuation and Metrics

With a P/E Ratio of 37.51 and an EV/EBITDA of 18.06, the company's valuation appears to be pricing in significant growth expectations. The company's ROE of 4.83% and ROIC of 4.13% indicate a relatively stable return profile. Analysts estimate next year's revenue growth at 5.2%, which is slightly higher than the company's current growth rate.

Operational Highlights

The company is focused on delivering consistent market share gains for CooperVision, investing in sales and marketing initiatives, and maintaining a disciplined approach to capital allocation. The company has a low debt leverage ratio and $1 billion in authorization available for share buybacks, which is a high priority given the current stock price.

Future Prospects

3. NewsRoom

Card image cap

Chesapeake Utilities CFO Beth Cooper announces retirement, COO Jeff Sylvester named successor

Mar -24

Source: prnewswire.com

Card image cap

COO or SAUHY: Which Is the Better Value Stock Right Now?

Mar -18

Source: zacks.com

Card image cap

Touchstone Mid Cap Fund Q4 2025 Portfolio Review

Mar -15

Source: seekingalpha.com

Card image cap

The Cooper Companies (COO) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Mar -11

Source: zacks.com

Card image cap

Investing in The Cooper Companies (COO)? Don't Miss Assessing Its International Revenue Trends

Mar -09

Source: zacks.com

Card image cap

Is The Cooper Companies (COO) a Solid Growth Stock? 3 Reasons to Think "Yes"

Mar -06

Source: zacks.com

Card image cap

COO Declines Despite Q1 Earnings Beat and Raised FY26 Outlook

Mar -06

Source: zacks.com

Card image cap

The Cooper Companies, Inc. (COO) Q1 2026 Earnings Call Transcript

Mar -06

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.00%)

6. Segments

CooperVision

Expected Growth: 6.0%

CooperVision's 6.0% growth is driven by increasing demand for silicone hydrogel contact lenses, expansion in emerging markets, and strategic investments in digital marketing and e-commerce platforms. Additionally, the company's focus on innovative products, such as daily disposable lenses, and its strong relationships with eye care professionals contribute to its growth momentum.

CooperSurgical

Expected Growth: 6.0%

CooperSurgical's 6.0% growth driven by increasing demand for women's healthcare and fertility treatments, expansion in emerging markets, and strategic acquisitions. Additionally, investments in product innovation and digitalization are enhancing customer experience, contributing to revenue growth.

7. Detailed Products

Clariti 1-Day

Daily disposable contact lenses designed for comfort and clarity

Clariti 1-Month

Monthly disposable contact lenses for clear and comfortable vision

Biofinity

Monthly disposable contact lenses for astigmatism and presbyopia

Avaira

Two-weekly disposable contact lenses for comfort and clarity

Paragon CRT

Orthokeratology (OK) lenses for overnight wear to correct vision

Syringeal IOL

Intraocular lenses for cataract surgery

Clariti 1-Day Toric

Daily disposable contact lenses for astigmatism

8. The Cooper Companies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for The Cooper Companies, Inc. is medium due to the presence of alternative products and services in the medical device industry.

Bargaining Power Of Customers

The bargaining power of customers for The Cooper Companies, Inc. is low due to the company's strong brand reputation and diversified product portfolio.

Bargaining Power Of Suppliers

The bargaining power of suppliers for The Cooper Companies, Inc. is medium due to the presence of multiple suppliers in the market, but the company's large scale of operations gives it some bargaining power.

Threat Of New Entrants

The threat of new entrants for The Cooper Companies, Inc. is low due to the high barriers to entry in the medical device industry, including regulatory hurdles and high research and development costs.

Intensity Of Rivalry

The intensity of rivalry for The Cooper Companies, Inc. is high due to the presence of several established competitors in the medical device industry, leading to intense competition for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 25.39%
Debt Cost 5.75%
Equity Weight 74.61%
Equity Cost 8.81%
WACC 8.03%
Leverage 34.02%

11. Quality Control: The Cooper Companies, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Merit Medical Systems

A-Score: 4.2/10

Value: 2.7

Growth: 7.3

Quality: 5.3

Yield: 0.0

Momentum: 2.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
DENTSPLY SIRONA

A-Score: 4.2/10

Value: 7.3

Growth: 1.6

Quality: 2.8

Yield: 7.0

Momentum: 1.0

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Teleflex

A-Score: 3.7/10

Value: 6.2

Growth: 3.4

Quality: 5.1

Yield: 1.0

Momentum: 1.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Repligen

A-Score: 3.6/10

Value: 0.4

Growth: 5.0

Quality: 5.1

Yield: 0.0

Momentum: 7.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Azenta

A-Score: 3.3/10

Value: 5.1

Growth: 4.4

Quality: 4.8

Yield: 0.0

Momentum: 2.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Cooper

A-Score: 3.2/10

Value: 2.6

Growth: 2.0

Quality: 5.8

Yield: 0.0

Momentum: 2.0

Volatility: 6.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

70.21$

Current Price

70.21$

Potential

-0.00%

Expected Cash-Flows